Fox Run Management’s Aerie Pharmaceuticals AERI Stock Holding History

Fox Run Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-9,338	Closed	-$276K	–	618
2019 Q2	$276K	Buy	+9,338	New	+$360K	0.18%	261
2018 Q4	–	Sell	-3,269	Closed	-$201K	–	804
2018 Q3	$201K	Buy	+3,269	New	+$210K	0.09%	478
2018 Q2	–	Sell	-4,112	Closed	-$223K	–	973
2018 Q1	$223K	Buy	+4,112	New	+$230K	0.05%	596
2017 Q4	–	Sell	-7,300	Closed	-$355K	–	947
2017 Q3	$355K	Sell	7,300 -4,700	-39%	-$256K	0.1%	428
2017 Q2	$631K	Buy	12,000 +2,442	+26%	+$114K	0.22%	144
2017 Q1	$433K	Buy	9,558 +3,158	+49%	+$141K	0.18%	239
2016 Q4	$242K	Buy	+6,400	New	+$242K	0.13%	372

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Fox Run Management's AERI Position: Q3 2019 in Review

Fox Run Management sold out of Aerie Pharmaceuticals (AERI) in Q3 2019, closing a stake of 9,338 shares — an estimated $276K sold.

Fox Run Management first reported a position in AERI in Q4 2016 and held it in 7 quarters. The position peaked at $631K in Q2 2017. 167 funds tracked by Wall St. Rank hold AERI as of Q3 2019.

Fox Run Management reported no remaining Aerie Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Fox Run Management sold 9,338 Aerie Pharmaceuticals shares in Q3 2019, an estimated $276K.
Fox Run Management first reported a position in Aerie Pharmaceuticals in Q4 2016 and held it in 7 quarters.
Fox Run Management's Aerie Pharmaceuticals position peaked at $631K in Q2 2017.
167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2019.

Based on Fox Run Management's 13F filing for Q3 2019, filed 11 Oct 2019.